SCHEMBL25178787

SCHEMBL25178787

COc1cc(Br)cc(Cc2nncn2C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HSP90AB1 P08238 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
ATM Q13315 1/20 0.33
KDM4E B2RXH2 2/20 0.32
CBLB Q13191 1/20 0.32
MAPK1 P28482 2/20 0.32
CRHR1 P34998 1/20 0.32
MAPT P10636 2/20 0.31
F2 P00734 1/20 0.31
CALM1 P0DP23 1/20 0.31
PKM P14618 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891999 1.00 HTR1A (0.36) HTR1AHTR2CALDH1A1HSP90AB1KMT2A
SCHEMBL25186525 0.86 HTR1A (0.40) HTR1AHTR2CALDH1A1KMT2AMEN1
SCHEMBL31275071 0.86 HTR1A (0.34) HTR1AHTR2CALDH1A1KMT2AKDM4E
SCHEMBL31275006 0.85 HTR2C (0.34) HTR1AHTR2CALDH1A1CBLB
SCHEMBL31274790 0.81 MAOB (0.45) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL25182795 0.79 HTR1A (0.37) HTR1AHTR2CALDH1A1KMT2AMEN1
SCHEMBL25180165 0.79 HTR1A (0.37) HTR1AHTR2CALDH1A1KMT2AMEN1
SCHEMBL30374541 0.79 HTR1A (0.37) HTR1AHTR2CALDH1A1KMT2AMEN1
SCHEMBL30374388 0.79 HTR1A (0.37) HTR1AHTR2CALDH1A1KMT2AMEN1
SCHEMBL25186409 0.75 HTR1A (0.43) HTR1AHTR2CMAPK1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187709-B2 Lactams as CBL-B inhibitors selective over C-CBL GENENTECH, INC. (US) 2025-01-07 US disclosed
EP-4426691-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL Genentech, Inc. (US) 2024-09-11 EP disclosed
US-20230212153-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL GENENTECH, INC. (US) 2023-07-06 US disclosed
WO-2023081853-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL GENENTECH, INC. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212153-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL CBL, CBLB, CBLC HTR1A 4122/4885HTR2C 4036/4885ALDH1A1 3554/4885
US-12187709-B2 Lactams as CBL-B inhibitors selective over C-CBL CBL, CBLB, CBLC HTR1A 4122/4885HTR2C 4036/4885ALDH1A1 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.